Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) – Research analysts at SVB Leerink issued their FY2027 earnings per share estimates for Eledon Pharmaceuticals in a report released on Tuesday, January 10th. SVB Leerink analyst T. Smith anticipates that the company will earn ($2.28) per share for the year. The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($2.61) per share.
Get
Eledon Pharmaceuticals alerts:
Separately, HC Wainwright reiterated a "buy" rating on shares of Eledon Pharmaceuticals in a research report on Thursday, December 15th.
Eledon Pharmaceuticals Trading Down 2.1 %
Shares of Eledon Pharmaceuticals stock opened at $2.79 on Wednesday. The business's 50 day simple moving average is $2.49 and its 200-day simple moving average is $2.81. The stock has a market capitalization of $38.38 million, a price-to-earnings ratio of -1.05 and a beta of 1.81. Eledon Pharmaceuticals has a twelve month low of $2.03 and a twelve month high of $5.14.
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.05).
Hedge Funds Weigh In On Eledon Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP bought a new position in Eledon Pharmaceuticals in the 3rd quarter worth approximately $50,000. Renaissance Technologies LLC boosted its stake in Eledon Pharmaceuticals by 35.1% during the 1st quarter. Renaissance Technologies LLC now owns 18,473 shares of the company's stock valued at $73,000 after purchasing an additional 4,800 shares in the last quarter. State Street Corp boosted its stake in Eledon Pharmaceuticals by 10.5% during the 1st quarter. State Street Corp now owns 44,692 shares of the company's stock valued at $176,000 after purchasing an additional 4,257 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in Eledon Pharmaceuticals by 13.2% during the 3rd quarter. Ensign Peak Advisors Inc now owns 87,286 shares of the company's stock valued at $241,000 after purchasing an additional 10,186 shares in the last quarter. Finally, CM Management LLC boosted its stake in Eledon Pharmaceuticals by 8.9% during the 3rd quarter. CM Management LLC now owns 245,000 shares of the company's stock valued at $676,000 after purchasing an additional 20,000 shares in the last quarter. 45.59% of the stock is owned by institutional investors.
Eledon Pharmaceuticals Company Profile
(Get Rating)
Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
Further Reading
- Get a free copy of the StockNews.com research report on Eledon Pharmaceuticals (ELDN)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
